Has Naiyer Rizvi received payments from drug or device companies?

Yes. Drug and device makers reported $138,640 in general payments to Naiyer Rizvi across 133 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Naiyer Rizvi did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Naiyer Rizvi come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Naiyer Rizvi

Medical Oncology · New York, NYNPI 1154392066

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $105,297 of the $138,640 with a category attached, or 75.9%. It is spread thinly across 19 manufacturers, the largest accounting for just 20.4%. Reporting peaked in 2019 at $86,373 and has fallen 100.0% since, to $34 in 2025.

$138,640in general payments, 2019–2025

Across 133 payments — averaging $1042.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$28K
Merck$20K
Astrazeneca UK Limited$13K
EMD Serono, Inc.$12K
Regeneron$12K
Sanofi$7K
plus $47K from 13 others

$1,765,162in research payments, 2019–2025

Across 129 payments — averaging $13,683 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Genentech, Inc.$519K
Merck$414K
AstraZeneca$272K
F. Hoffmann-la Roche AG$111K
Exelixis Inc.$106K
GSK$90K
plus $253K from 7 others

What the payments were for

Consulting fees$105,29776%
Speaking & faculty fees$3,9673%
Travel & lodging$22,54716%
Food & beverage$6,7455%
Education$850%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	25	$28,287
Merck	11	$19,978
Astrazeneca UK Limited	11	$13,430
EMD Serono, Inc.	5	$11,970
Regeneron	5	$11,754
Sanofi	2	$6,563
E.r. Squibb & Sons, L.L.C.	18	$5,987
Boehringer Ingelheim	18	$5,950
Gilead	6	$5,199
Foundation Medicine, Inc.	5	$5,092
Genentech, Inc.	4	$4,658
Janssen Scientific Affairs, LLC	4	$4,040
Shionogi Inc	1	$4,000
Pfizer	4	$3,175
Eli Lilly	2	$2,856
F. Hoffmann-la Roche AG	6	$2,284
Eisai CO., LTD.	1	$1,875
Amgen	3	$1,415
GSK	2	$128

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$138,640 in reported general payments places this provider in the 85th percentile of 498 medical oncology providers in New York.

See all medical oncology providers in New York →

Other medical oncology in New York

Craig ThompsonNew York$4.8M
Andrew SeidmanNew York$1.3M
Joshua RichterNew York$971K
Edward GelmannNew York$944K
Ghassan Abou-AlfaNew York$825K
Miguel PeralesNew York$769K
Komal JhaveriNew York$642K
Joshua BrodyNew York$492K
Aiwu HeNew York$445K
Raajit RampalNew York$418K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →